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a b s t r a c t
To assist practices and institutions throughout the country in implementing clinical redesign supported
by - and aligned with - payment reform, we present a case study of the New Mexico Cancer Center
(NMCC) based on numerous stakeholder interviews, literature reviews, and a comprehensive site visit.
This study explores the complex barriers oncologists face in improving the quality and outcomes of
cancer care and reducing overall costs in a sustainable way. This case will explore the following
questions: How did the NMCC redesign care to improve quality, enhance patient experience and results,
and reduce costs? How can an organization demonstrate they are improving quality to enable new
payment contracts that enable sustainability? Are alternative payment models sustainable for an
independent, community oncology practice?
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Background
To assist practices and institutions throughout the country in
implementing clinical redesign supported by – and aligned with –
payment reform, we present a case study of the New Mexico
Cancer Center (NMCC) based on numerous stakeholder interviews,
literature reviews, and a comprehensive site visit. This study
explores the complex barriers oncologists face in improving the
quality and outcomes of cancer care and reducing overall costs in a
sustainable way. This case will explore the following questions:
how did the NMCC redesign care to improve quality, enhance
patient experience and results, and reduce costs? How can an
organization demonstrate they are improving quality to enable
new payment contracts that enable sustainability? Are alternative
payment models sustainable for an independent, community
oncology practice?
2. Personal context
Vicky Bolton, a 58 year old fulltime medical legal coordinator
from Albuquerque, has stage 4 adenocarcinoma lung cancer and
started chemotherapy in 2003. Although her condition is stable,
she is at high risk for venous thrombosis (blood clots), life-
threatening infections, and other complications, which put her at
high risk for repeated hospitalizations. Each of her providers and
services – oncology, radiation therapy, labs, x-rays, and internal
medicine – are centralized in a single location at NMCC, which has
expanded, comprehensive after-hours care. In the past six months,
she has taken advantage of this program on three occasions as an
outpatient at NMCC and avoided emergency room and inpatient
care. However, the lack of sustainable payment model has placed
NMCC's after-hours program in jeopardy.
3. Problem
Cancer is the second leading cause of death in the U.S1and 41%
of Americans will be diagnosed with cancer at some point during
their lives. Cancer care is also expensive. In 2010 it accounted for
$125 billion in health care spending and is expected to cost at least
$158 billion by 2020.2
The high costs of cancer care are driven by issues that plague the
entire health system: uncoordinated care delivery, duplication of
services, and fragmentation. A common impact of these cost drivers
in oncology is the use of emergency room (ER) visits for symptom
relief from the adverse side effects of treatment, which often leads
to hospitalization. For example, one study showed that the most
common reasons for cancer patient ER admissions were pain,
respiratory distress, nausea, and vomiting – more than half of the
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ER visits occurred on weekends or in the evening, and over 60%
resulted in hospital admission.3
The current fee-for-service payment system further exacerbates
problems. Firstly, many of the clinical reforms to provide higher-
value care to patients at a lower cost are reimbursed poorly if at all
under fee-for-service. Secondly, to the extent that the clinical
reforms reduce costly complications that are reimbursed, the
ﬁnancial savings accrue only to the payer, not the individual
practice responsible for implementing many of the reforms.
4. Catalyst for change
Dr. Barbara McAneny founded the New Mexico Cancer Center
(NMCC) in 1987 and in her years working as a medical oncologist,
she has been particularly frustrated by the adverse impact that
fragmented care has had on her patients. Often patients are
directed to up to three different locations to receive care from
their oncologist, lab tests, and chemotherapy treatments. NMCC
created an independent, free-standing, integrated community
cancer center designed around patient needs.
5. Solution
In this study, we use a care redesign framework (Fig. 1) to
consider the speciﬁc elements undertaken by NMCC as they
improve quality patient-centered care at a reduced cost.
6. Care redesign strategies
Over the past 15 years, NMCC has redesigned where care is
delivered; who care is delivered by; how care decisions are made;
and the data used to ensure effectiveness (see Fig. 2). To make
these intended transformations ‘come alive’, extensive engage-
ment has been undertaken with both patients and clinicians.
6.1. Purpose built center to deliver care
NMCC bought land to build their center in 2001 and the patient
perspective had an impact in all areas of buidling design and décor.
The center itself is a single-story building with a parking lot right
outside so that patients do not need to walk a long way to and from
their treatments. The internal layout of the building has also been
speciﬁcally designed to feel more like home, less like an austere,
health care institution. The doctors ofﬁces are arranged in 3 ‘pods’
with a central desk with medical assistants to support patients and
clinicans, rather than one large and overwhelming ofﬁce.
6.2. Provide all services in one community location
Geographic clustering of care can lead to better patient satis-
faction and a reduction in unnecessary duplication of service
through improved compliance with medication administration,
lab testing, and follow-up. By having everything from diagnostic
imaging to lab services and chemotherapy all available in one
place, NMCC has created a centrally located hub for services,
instead of forcing patients across multiple providers and sites of
care. By providing this all in a community setting ensures that the
rates paid for services are lower than they would be in a hospital
inpatient or outpatient department. For example, the cost of
receiving chemotherapy, per beneﬁciary, in a hospital was 25–
47% higher than in a physician ofﬁce from 2009 to 2011.4
6.3. Designated care coordinators in care teams
Each physician is paired with a patient care coordinator (PCC)
and they share a case-load. The PCC takes all routine non-clinical
work from the doctor so that they can work at the top of their
license. They also work with patients and book all appointments,
schedule required treatments, and arrange travel when needed.
Fig. 1. Care redesign framework.
Fig. 2. Care redesign elements undertaken by NMCC.
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This helps reduce delays in treatment and allows the patient to
focus solely on their treatment and recovery.
6.4. Funding strategy
Most of these redesign initiatives did not have direct ﬁnancial
support and funding came from reinvestment of NMCC proﬁts in
the early 2000s. Following failed attempts to secure payer funding
for enhanced services, additional ﬁnancial support came in 2012
from a $19.8 million grant awarded by the Center for Medicare and
Medicaid Innovation (CMMI) to NMCC and six other oncology
practices for a program called COME HOME (see Figs. 3 and 4). The
program is tasked with demonstrating improved outcomes,
enhanced patient care, and lowered costs, and has an explicit
aim to reduce ER visits by 50% and hospitalization by 20% to justify
the program costs.
The major areas of redesign through the COME Home program
were the extended hours of practice and improved triage decision-
support.
6.5. Expand access through after hours care
Prior to the project, NMCC closed at 5 pm on weekdays and
offered no weekend hours. The center is now open until 8pm on
weekdays and 1–4 pm on weekends. In addition to the physicians
and nurses operating at these times, the in-house lab is also open
to ensure that physicians have access to the tests and test results
required to treat patients effectively. To help manage this as
effectively as possible, NMCCs hired an urgent care physician to
treat patients experiencing side-effects. Prior to the implementa-
tion of the ﬁlgastrim (Neupogen) shot clinic on weekends, patients
had to visit an emergency department or inpatient facility to
receive shots, pay high drug- and visit-copayments, and often wait
several hours in an environment with high risk of infection from
other ill patients. At the end of quarter seven of operation, NMCC
has averaged 82 extended hours' visits per month accounting for
approximately 14% of all patient visits.
6.6. Improved decision support
NMCC has worked to improve their decision-support for both
physicians and nursing staff. The physician support has been
focused on diagnostic and therapeutic pathways (intend to guide
physicians toward the most effective treatments, and in the event
that two treatments have the same efﬁcacy, toward the least
expensive one) and the nursing support has been in the Triage
Pathways.
NMCC now have clinical (diagnostic and therapeutic) pathways
for seven tumor types, which account for 75% of their patients.
They are currently at 80% adherence to their pathways and have
started to look at other measures for diagnostic and therapeutic
excellence.
The Triage Pathways support decision making when patients
call with acute symptoms or questions. Previously, only experi-
enced oncology registers nurses (RNs) and licenses practical
nurses (LPNs) provided patient assistance via telephone, limited
to the hours of 8 am and 5 pm, and there were no formal written
processes in place. This led to lengthy calls with patients, variation
in the information patients were given, and possible preventable
visits to ERs and hospitalizations.
6.7. Collecting and using data
Before any data is collected, NMCC develop a schema outlining
the intended use and the decisions it will underpin (clinical
actions to improve care). Quality measures are not considered
static and, once achieved, are amended with more rigorous targets
(Fig. 5).
NMCC would like to use claims data from CMS and other payers
to help identify opportunities for improvements in care, but they
have not managed to solve some of the key data sharing issues
involved, including privacy concerns and the timely access to
information.
6.8. Patient surveys
NMCC uses a patient satisfaction survey developed by Commu-
nity Oncology Alliance (COA), based on the Consumer Assessment
of Healthcare Providers and Systems (CAHPS) methodology.5 The
COA survey includes questions that could be turned into quality
Fig. 3. Breakdown of grant allocation by cost category.
Source: information provided by NMCC and COME Home Innovative Oncology
Business Solutions, Inc. staffs through emails following interviews.
Fig. 4. Breakdown of grant allocation by clinic.
Source: information provided by NMCC and COME Home Innovative Oncology
Business Solutions, Inc. staffs through emails following interviews.
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measures for actionable data. Three areas of focus include whether
patients received their care right away, whether patients received
all the information they wanted about their health to share in
decision making, and whether patients felt they were treated them
with respect.
6.9. Technology
NMCC's EHR is Varian's ARIA. It was originally purchased, as
part of NMCC's proﬁt reinvestment in the early 2000s, for
$450,000 and the practice spends $500,000 annually for licenses
and maintenance. The diagnostic, therapeutic, and Triage Path-
ways are integrated into the EHR and provides near to real-time
reporting (with twice-daily data sync). Recent improvements to
the system include ability to input DNR discussions (a key quality
metric), co-morbidities, and family history. NMCC took into
account “meaningful use” requirements when designing the
speciﬁcations for their EHR – the federal legislation that ties
incentive payments to using certiﬁed EHR technology and adopt-
ing required objectives and measures. In future enhancements,
NMCC are aiming to develop predictive analysis to target
interventions.
7. Alternative payment models (APMs) to sustain care redesign
Fig. 6 describes APMs in development for oncology are in the
early stages but all, to varying degrees, work towards transitioning
to a more comprehensive episode- or case-based payment, and
reducing or limiting FFS payments for some services, in order to
enable more ﬁnancial support for the types of care redesign
activities that are not reimbursed under FFS.6
7.1. Payment for clinical pathways adherence
Clinical pathways, based on National Comprehensive Cancer
Network (NCCN) guidelines, are considered by many to be the ﬁrst
step towards a more comprehensive payment and delivery reform
option in oncology. The other alternative payment models described
below include adherence to pathways as part of their reform.
The clinical pathways model itself uses an add-on per-patient
payment to encourage adherence to predeﬁned, evidence-based
chemotherapy regimens. A provider adopts clinical pathways into
their workﬂow and, in doing so, agrees to use a preselected group
of triage, diagnostic, and/or therapeutic treatments; for treatments
that have been shown to be equal in clinical effectiveness (and
minimizing side effects), the clinical pathways will recommend
the treatment with the lowest cost (Fig. 7).
Preliminary ﬁndings from pilot studies of clinical pathways
suggest the initiatives have had an impact on costs without
worsened outcomes. One study of a cohort of lung cancer patients
showed a reduction in drug costs of 37% over the course of the 12
month study. A majority of these savings were associated with
adjuvant and ﬁrst-line chemotherapy drugs with no cost saving
found in second-line settings.7 A more conservative cost reduction
estimate comes from WellPoint, which recently begun offering
oncologists a $350 per-member-per-month payment for each
cancer patient on a pathway, and estimates 3–4% reductions in
treatments costs per year.8
7.1.1. Potential opportunities and barriers of clinical pathways for a
community oncology practice
While clinical pathways do require commitment from physi-
cians to develop and update, they do not require major structural
changes to implement. They therefore represent a good starting
place for a practice to start to reduce variation between individual
physicians and potentially reduced costs. The major barrier to
Fig. 5. Key measures collected by NMCC.
Fig. 6. Comparison of alternative payment models for oncology.
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using clinical pathways as a payment model is whether a practice
can ﬁnd a payer who is willing pay a case fee for compliance to
standard.
A practice may choose to view clinical pathways not as an APM
in itself, but as an important quality initiative which will provide
assurance to payers to underpin other alternative payment models.
7.2. Patient-centered oncology medical home
The PCOMH includes a ﬁxed PMPM fee for clinicians that meet
a speciﬁc set of capabilities and quality standards in their prac-
tices, using an adaptation of the primary care patient-centered
medical home framework established by the National Committee
for Quality Assurance (NCQA). This fee can be used to support
services not reimbursed by FFS of for infrastructure investments
such as additional staff time for patient care, care coordination,
and better decision support for care management.
The initiation of the payment model begins with a patient's
diagnosis and the case payment in oncology is generally between
$200 and $250 PMPM which is signiﬁcantly higher than the $5–20
PMPM received in primary care due to the additional complexity
of the care delivered to cancer patients.6 (Fig. 8)
Preliminary ﬁndings from of care and cost savings from
PCOMHs have been promising. The most well-known PCOMH is
pioneered by Dr. John Sprandio and his colleagues at the Con-
sultants in Medical Oncology and Hematology (CMOH), a small
physician practice outside of Philadelphia. In 2010, CMOH was the
ﬁrst oncology practice to be recognized by the NCQA as a level III
PCMH.9
Early results showed that ED visits at the practice fell by 68%,
hospital admissions per patient treated with chemotherapy fell by
51%, and the length of stay for admitted patients fell by 21%10,6.
CMOH estimates that the aggregated savings to CMOH payers is
approximately $1 million per physician per year through reductions
in the cost of care for the clinically vulnerable-patients that are
older, chronically ill, and with multiple comorbidities.
7.2.1. Potential opportunities and barriers of PCOMHs for a
community oncology practice
A practice which already redesigned care to a medical home
model would be well positioned to implement this payment
model. However, establishing the required PMPM or the amount
the practice could save the overall system if ER visits and
hospitalizations are reduced will be almost impossible without
access to claims data from both commercial and federal payers.
Practices that have not yet redesigned care may ﬁnd that, without
clear evidence that the up-front payment will lead to quality
improvements that succeed in reducing overall costs of care, may
ﬁnd payers to be reluctant to agree to the additional payments
required to implement the required changed.
Further, even if the data issues facing a particular payer can be
addressed, it is necessary that a payer must have enough market
share to act alone and sustain the payment model. The medical
home is difﬁcult to implement for only one payer's patients, for
both technical and professional practice reasons. If only one payer
implemented the payment reform, the PMPM for supporting the
medical home would apply to only a fraction of patients, making it
difﬁcult to sustain the costs of maintaining medical home services
and capabilities for their entire practice.
7.3. Oncology accountable care organizations (ACO)
The oncology ACO framework introduces a shared saving
model based on overall patient costs and quality of care in
addition to FFS reimbursement. It builds on this alternative
payment approach over time with an aim to moving more
reimbursement from FFS towards a partially capitated payment
for a broader range of oncology services. A group of providers are
Fig. 8. Reduction in overall cancer costs through implementation of a PCOMH.
Fig. 7. Reduction in overall cancer costs through implementation of clinical pathways.
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held accountable for the overall quality, cost, and care of their
patient population and share the savings recouped form better
coordinated, higher quality care (Fig. 9).
Two early oncology ACO models were developed in Florida
with the local BCBS health plan, Florida Blue. The ﬁrst was a joint
program between Baptist Health South Florida and Advanced
Medical Specialties, and the second was with Mofﬁtt Cancer
Center. There are approximately 1000 patients across both ACOs
and the model stratiﬁes risk only by type of cancer. The models
target the overall cost of care, not just their oncology care, running
for one year from ﬁrst diagnosis.11
One key challenge to developing these models was deﬁning
measurements – particularly how to deﬁne and attribute cancer
cases. The sharing of data between provider and payer was crucial
and outside counsel was required to address these and other
issues (e.g., data privacy protections). The solution reached was to
consider full utilization except mental and behavioral health and
utilization and spending benchmarks were developed by actuaries
within Florida Blue.
The results of these models have included early clinical
successes, with signiﬁcant reductions in hospital admissions and
readmissions, better generic drug prescribing rates, greater adher-
ence to pathway and evidence-based protocols, and better coordi-
nated care.12 The ﬁnancial successes are less clear and, because of
variations in costs of care, are difﬁcult to discern with high
statistical conﬁdence.
7.3.1. Potential opportunities and barriers of ACOs for a community
oncology practice
To become part of a successful ACO, a practice must form part
of a large, cohesive, coordinated network which can share data to
attribute patients and shared savings appropriately6. Locating
ACO partners will be a challenge for any community oncology
practice if, as in Albuquerque, there is a large integrated health
system with its own hospital-based oncology practice in the
local area.
7.4. Bundled payments
A bundled payment is a combined payment for a package of
clinically related services in a case or episode of care, including
multiple services from a particular provider or the services of
multiple providers. The bundled payment may be a ﬁxed price
paid prospectively, or a benchmark that is used to adjust net
payments to the providers retrospectively. It is designed to
appropriately compensate clinicians for the comprehensive set of
services required to meet patient's needs for the episode of care, as
opposed to billing for each individual test, procedure, and service
provided. Bundled payment enables clinicians to redirect
resources to services that are not currently compensated, and
requires clinicians to take accountability for the overall cost of the
episode (Fig. 10).
Bundled proposals for oncology include a pilot focusing on
multi-practice episode-based payment for chemotherapy drug
administration (United Healthcare13) pilots for a broader set of
bundled services for speciﬁc cancer types (Fox Chase and Horizon
BCBS14, and 21st Century Oncology and Humana15), and a pilot for
bundling radical prostatectomy early stage patients (Mobile Sur-
gery International and Florida Blue). Most of these pilots involve
limited or partial shifts of FFS payments into episode-based
payments. While CMMI is exploring bundled payment options
for acute and post-acute care through the Bundled Payments for
Fig. 9. Reduction in overall cancer costs through implementation of an ACO.
Fig. 10. Reduction in overall cancer costs through implementation of a bundled payment model.
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Care Improvement (BPCI) Initiative, the payment options do not
include or target comprehensive cancer care.16
7.4.1. Potential opportunities and barriers of bundled payments for a
community oncology practice
To be able to develop a bundle of services, a practice must be
able to assess the extent to which it could take on accountability
for the costs of services provided. Payers need to be both able and
willing to share this information so that complete claims data can
be used to analyze costs, and practices need the actuarial capacity
to analyze this data appropriately.
Additionally, early understanding of which patients and services
do or do not ﬁt into a bundle is challenging, especially for broader
bundled payments, and would require near-to real-time monitoring
across the network for providers included in the bundle. Imple-
menting a broad bundle is made even more complex by the fact
that treatments are constantly developing and changing – treat-
ments that are standard nowmay be quite different in a year's time.
While some organizations have begun work on creating com-
prehensive bundled payments for cancer, only more limited
bundled payment pilots like those described above are currently
in operation. These limited payment reforms may not be sufﬁcient
to support the major care reforms envisioned by a practice to
achieve better outcomes and substantial savings. However, imple-
menting an oncology medical home with supporting payment
could be a basis for developing the data and systems needed to
support effective implementation of bundled payment.
8. Recommendations for NMCC
The goal for NMCC is to ﬁnd a payment model to recover the
amount of initial investment and support the continued efforts of
the COME HOME program to provide services to all of NMCC's
patient population, not only those of a particular payer. Because no
single payer has a substantial market share (see Fig. 11), payers
may be reluctant to subsidize a service which could potentially be
underwritten by another payer.
Of payment reform options, NMCC has been unable to contract
as part of a comprehensive ACO due to local health care market
conditions. Clinical pathways are geared primarily to guidelines
and chemotherapy adherence, and are not designed to provide
funding for after-hours care or triage programs that are intended
to achieve offsetting savings through avoiding costly complica-
tions. Possible remaining options include the following:
8.1. Option 1: PCOMH with accountability
Using the data it gathers, NMCC intends to quantify the
additional costs the COME HOME model requires, and the savings
that it achieves. Using that estimate, NMCC could suggest a per-
member per-month (PMPM) payment from a private insurer to
cover the costs of providing higher quality care. To encourage
participation, NMCC could also enter into a risk-sharing agree-
ment, in which overall costs of inpatient care and ER visits would
be compared against a target. The PMPM could be at-risk if the
targets are not achieved after a certain period of time.
8.2. Option 2: PCOMH with accountability to support transition
toward bundled payment
While an oncology bundled payment is NMCC's long-term
preferred model, an interim possibility might be to use the
medical home approach with risk sharing (described above) as a
ﬁrst step toward a bundled payment system. Computing actua-
rially sound expected costs for the bundled payments would
require merging claims data with clinical data (for example, ICD-
9 codes fail to distinguish between subtypes of breast cancer that
have radically different treatments). A limited bundled payment
pilot might be performed initially for high volume cancers, such as
breast and lung.
8.3. Option 3: enhanced FFS through public or private insurance
NMCC could seek to modify the existing model with enhanced
fee-for-service payments to cover out of hours visits and
telephone-based triage services. However, this simply adds to
the fee-for-service arrangements, and payers may be reluctant to
support due to concerns that it would primarily generate addi-
tional billing rather than better care coordination, care transfor-
mation, and reductions in overall costs.
8.4. Option 4: direct contracting with major employers
Finally, given the challenges of working with payers in its
market, NMCC could consider directly contracting for oncology
services (known as a carve out) with major employers (see Fig. 12
for a list of the top employers). There is a precedent, in which Intel
has entered into an ACO-type arrangement with Presbyterian
Hospital to provide medical services to employees through the
group health insurance sponsored by the employer.
All of these further options present difﬁcult challenges; as of
this writing, the long-term sustainability of the NMCC reforms
when its CMMI grant expires is unclear.
9. Lessons
The experience of innovative pioneers like NMCC can shed
some light on potential barriers to conceptualizing and imple-
menting sustainable clinical redesign.
Fig. 11. Breakdown of Payers NMCC. NOTES: Medicare is only accounting for
payments received from the government; Presbyterian's ﬁgure includes Medicare
Advantage, Managed Medicaid and commercial; Blue Cross Blue Shield's (BCBS)
includes Managed Medicaid and commercial; Indian Health Service (IHS) is
signiﬁcant in Gallup but not in overall market.
Source: information provided through interviews with NMCC staff.
Rank Organization City FTE
1 State of New Mexico (statewide) Santa Fe 21,832
2 University of New Mexico (statewide) Albuquerque 20,042
3 New Mexico State University (statewide) Las Cruces 12,737
4 Central New Mexico Community College Albuquerque 11,777
5 Albuquerque Public Schools Albuquerque 11,500
Fig. 12. Top ﬁve employers in New Mexico, 2011.
Source: NewMexicoNetLinks, Largest Employers in New Mexico.17
D. Sanghavi et al. / Healthcare 3 (2015) 160–168166
9.1. Relationships with payers and network
NMCC's experience illustrates that a prolonged commitment to
demonstrating signiﬁcant value from care redesign, particularly
from lower utilization of inpatient and emergency department
utilization, does not automatically create a ﬁnancial pathway for
sustainable delivery reform. Innovative providers that seek to
reform care should consider a sustainability path from the start.
This might include involving lead payer partners early on to help
identify end-points of interest to payers and potential payment
alternatives to traditional fee-for-service payment that could
support these reforms.
Providing support for health care delivery reforms requires
new activities by payers towards sharing data in new ways to
enable care improvements to be prioritized and implemented, and
aligning their payments with value, rather than volume and
intensity of services. However, fragmented health care markets
face challenges of the “free rider” problem (that is, payers may be
unwilling to shoulder delivery transformation costs that may
beneﬁt other payers' clients, and wait for CMS or others to make
the ﬁnancial investment, pay for the program evaluation, and
enact policy change), payer inertia, and long lag times between
care redesign and subsequent data demonstrating results.
Large ACOs and other integrated payer-provider plans, includ-
ing those large enough to form Medicare Advantage plans, are
moving forward on negotiating payment and delivery reforms.
This may be more difﬁcult for innovative, smaller practices, even if
they can provide higher-value clinical services. However, reliance
on very large providers may have anti-competitive consequences,
such as discouraging delivery innovation that leads to “demand
destruction” of high-cost hospital-based services.
For this reason, private and public payers should be particularly
interested in developing models that enable smaller, specialized
providers like oncology practices to undertake key delivery
reforms. Such specialty-speciﬁc payment models should be a high
priority for CMS and regional or national collaborations on pay-
ment reform involving multiple private payers.
9.2. Payment model selection
While substantial attention has been paid to primary care
focused APMs, specialty-focused APMs are needed for practices
like NMCC. Their development should be a high priority for public
and private payers.
Clinical transformation grants, such as those offered by CMMI,
should include clear pathways for transitioning to APMs if initial
quality improvement and cost savings targets are met. Otherwise,
delivery system innovations are at high risk of failure despite
evidence of improved value. Another approach to help assure
sustainability is for grants to require evidence of early payer
engagement with delivery transformation efforts, and early imple-
mentation of key steps like the use of standard measures that
could be a basis for APMs. Organizations such as ASCO have
offered policy solutions for payment reform which could apply
to both public and private payers as well incorporating elements of
bundled/episodic payments.18 These or other models now being
implemented could provide a good foundation for “best practices”
for smaller practices and payers to use to implement delivery and
payment reforms at a much lower cost.
9.3. Data collection and quality improvement considerations
Timely sharing of actionable information from claims and other
administrative data remains a major challenge, with complex and
varied procedures for obtaining claims from payers, and challenges
especially for smaller practices in interpreting the claims data.
Some states, such as Maryland, Massachusetts, Vermont, and
Colorado (among others) are proceeding with creating all-payer
claims databases.19 Maryland, for example, offers rapid provider
feedback on some key information for patient management from
claims through their CRISP database.20 Payers could also provide
such data to innovative practices directly, to build trust and
provide a needed foundation for payment and delivery reform.
In addition to producing performance measures from claims
data, more progress is needed to provide timely and actionable
data to enable practices to improve performance. As NMCC's early
efforts illustrate, practices can produce more clinically sophisti-
cated performance measures using the same clinical support
systems that enable improved patient care.
10. Conclusion
Unfortunately those at the leading edge of change in the last
decade are not necessarily in the position to beneﬁt most from
payment reform – they've already done a lot and there is relatively
little low-hanging fruit – payers do not want to have pay for
changes already made. In fact, diminishing returns to quality
improvement activities may actually be less costly for providers
at a low baseline level or performance that for one at a high level
(NMCC) to improve quality.21 These means that providers who
have either not engaged in signiﬁcant delivery reform or those
whose prices are already far above market averages stand to
beneﬁt the most from shared-saving arrangements, which tend
to penalize those who already work efﬁciently. It also means that
providers with high quality and low baseline costs must work that
much harder if incentives are based on quality improvement as
opposed to absolute quality.
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